Cyclo Therapeutics to Present at the Virtual Investor Roundtable Event
November 10 2021 - 8:05AM
Business Wire
Live moderated video webcast discussion with N.
Scott Fine, Chief Executive Officer and Lise Lund Kjems, MD, PhD,
Chief Medical Officer on Tuesday, November 16th at 11:00 AM ET
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or
the “Company”), a clinical stage biotechnology company dedicated to
developing life-changing medicines through science and innovation
for patients and families living with diseases, today announced
that N. Scott Fine, Chief Executive Officer and Lise Lund Kjems,
MD, PhD, Chief Medical Officer of Cyclo Therapeutics will
participate in the Virtual Investor Roundtable Event on Tuesday,
November 16, 2021 at 11:00 AM ET.
As part of the virtual event, the Company will provide a brief
presentation, followed by a moderated roundtable discussion and an
interactive Q&A session. In addition to the moderated portion
of the event, all investors and interested parties will have the
opportunity to submit questions live during the event. Interested
parties may also pre-submit questions in advance of the live event,
which can be sent via the conference website at
virtualinvestorco.com. The Company will answer as many questions as
possible during the event.
A live video webcast of the Roundtable Event will be available
on the Events page of the Investors section of the Company’s
website (cyclotherapeutics.com). A webcast replay will be available
two hours following the live presentation and will be accessible
for one year.
About Cyclo Therapeutics:
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology
company dedicated to developing life-changing medicines through
science and innovation for patients and families suffering from
disease. The Company’s Trappsol® Cyclo™, an orphan drug designated
product in the United States and Europe, is the subject of four
formal clinical trials for Niemann-Pick Disease Type C, a rare and
fatal genetic disease, (www.ClinicalTrials.gov NCT02939547,
NCT02912793, NCT03893071 and NCT04860960). The Company is planning
an early phase clinical trial using Trappsol® Cyclo™ intravenously
in Alzheimer’s Disease based on encouraging data from an Expanded
Access program for late-onset Alzheimer’s Disease (NCT03624842).
Additional indications for the active ingredient in Trappsol®
Cyclo™ are in development. For additional information, visit the
Company’s website: www.cyclotherapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211110005582/en/
JTC Team, LLC Jenene Thomas (833) 475-8247 CYTH@jtcir.com
Cyclo Therapeutics (NASDAQ:CYTH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cyclo Therapeutics (NASDAQ:CYTH)
Historical Stock Chart
From Apr 2023 to Apr 2024